Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study
ESC Heart Failure · 04.07.2026 · 13 (4)
DOI: 10.1093/eschf/xvag174 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 22.06.2026. Verfasst von Miloud Cherbi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, AZ Sint-Jan Hospital, Ruddershove 10, 8000 Bruges, Belgium. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Failure, Practice Guidelines as Topic, Adrenergic beta-Antagonists. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
While guideline-directed medical therapy (GDMT) is recommended for left ventricular assist device (LVAD) recipients, real-world evidence supporting its clinical impact remains limited. This study evaluated the association between GDMT prescription and clinical outcomes in LVAD patients.
Methods
This international retrospective multicentre study included 875 LVAD patients from 22 centres. Patients were categorized based on the number of GDMT (ACE-I/ARBs, beta-blockers, MRAs) prescribed. Primary outcome was 6-month all-cause mortality. Secondary outcome was late ventricular arrhythmias (VAs) (>30 days post-implant). Multivariable Cox regression and ordinal logistic regression analyses were performed.
Results
Overall, only 261 patients (29.8%) received triple GDMT, while 97 (11.1%) received no GDMT. After multivariable adjustment, the number of prescribed GDMTs was independently associated with improved survival, with aHRs for all-cause mortality of 0.51 (0.33–0.75, P < .01) for triple therapy, 0.39 (0.26–0.59, P < .01) for dual therapy, and 0.45 (0.30–0.67, P < .01) for single therapy, all compared with no GDMT. Similarly, ACE-I/ARB were associated with a lower risk of late VAs (aHR 0.65 [0.50–0.84], P < .01). Female sex, diabetes, early VAs, and higher bilirubin levels were associated with lower GDMT prescription rates. Major LVEDD improvement (≥10 mm reduction) increased progressively from 51.5% without GDMT to 66.1% with triple therapy.
Conclusion
In this large international study, the use of GDMT in LVAD patients was associated with improved survival, with benefits observed even with single-agent therapy. Despite these benefits, only 30% of patients received optimal triple therapy, highlighting the need for improved implementation strategies and standardized protocols in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, AZ Sint-Jan Hospital, Ruddershove 10, 8000 Bruges, Belgium.
- Cardiology Department, Toulouse University Hospital, Toulouse, France.
- Cardiology Department, CHU Saint-Etienne, Université Jean Monnet, Mines Saint-Étienne, Inserm U1059, SAINBIOSE, Saint-Étienne, France.
- Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany.
- Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.
- Division of Cardiology, University of Michigan, Ann Arbor, MI, USA.
ORCID-Profile: Miloud Cherbi, Clément Delmas, Paul Gautier, Karim Benali, Elena Efimova, Alexey Dashkevich, Jackson Liang, John Larson, Blandine Mondesert, Pierre-Emmanuel Noly, Jean-Baptiste Gourraud, Alexandre Sebestyen, Marylou Para, Frederic Anselme, Laure Champ-Rigot, Bertrand Pierre, Romain Eschalier, Mathieu Echivard, Nicolas Lellouche, Matteo Pozzi, Pierre Groussin, Raphael Martins
Zitieren
APA
Cherbi, M., Delmas, C., Gautier, P., Benali, K., Bode, K., Efimova, E., Dashkevich, A., Liang, J., Larson, J., Mondesert, B., Boulet, J., Noly, P. E., Picard, F., Pasquié, J. L., Gourraud, J. B., Ninni, S., Jesel, L., Sebestyen, A., Para, M., …, & Martins, R. (2026). Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study. ESC Heart Failure, 13(4). https://doi.org/10.1093/eschf/xvag174
Vancouver
Cherbi M, Delmas C, Gautier P, Benali K, Bode K, Efimova E, et al. Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study. ESC Heart Failure. 2026;13(4). doi:10.1093/eschf/xvag174
BibTeX
@article{Cherbi2026,
author = {Cherbi, Miloud and Delmas, Clément and Gautier, Paul and Benali, Karim and Bode, Kerstin and Efimova, Elena and Dashkevich, Alexey and Liang, Jackson and Larson, John and Mondesert, Blandine and Boulet, Jacinthe and Noly, Pierre-Emmanuel and Picard, François and Pasquié, Jean Luc and Gourraud, Jean-Baptiste and Ninni, Sandro and Jesel, Laurence and Sebestyen, Alexandre and Para, Marylou and Deharo, Jean-Claude and Anselme, Frederic and Champ-Rigot, Laure and M'Rabet, Soundous and Pierre, Bertrand and Eschalier, Romain and Echivard, Mathieu and Martin, Anne-Céline and Lellouche, Nicolas and Pozzi, Matteo and Groussin, Pierre and Flecher, Erwan and Galand, Vincent and Martins, Raphael},
title = {Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study},
journal = {ESC Heart Failure},
year = {2026},
volume = {13},
number = {4},
doi = {10.1093/eschf/xvag174}
}
EUVIMED